Drug Discovery Featured Articles & Applications

  1. The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future 6/23/2026

    The American Diabetes Association 2026 conference showed where we are and where we're going with GLP-1 therapies.

  2. Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire 6/19/2026

    We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.

  3. Aligning Standards, Validation, And Governance For Digital Preclinical Research 6/18/2026

    No single body integrates preclinical data components into a coherent discipline supported by shared standards, common terminology, and collective accountability.

  4. How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3) 6/15/2026

    Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.

  5. Can Molecular Glue Degraders Make The Undruggable Druggable? 6/12/2026

    Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.

  6. 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics 6/12/2026

    Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.

  7. 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics 6/11/2026

    Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.

  8. 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio 6/11/2026

    Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.

  9. 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics 6/10/2026

    Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.

  10. 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore 6/10/2026

    Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.